Skip to main navigation
Logo

Investor Relations

  • About Us
    • History
    • Our Leadership
    • Our Board of Directors
  • Pipeline
    • Mechanism of Action
    • Indications
    • Posters & Presentations
  • For Patients
  • For Investors
    • Overview
    • Stock Information
      • Stock Quote/Chart
    • News & Events
      • News Releases
      • Investor Calendar
      • Presentations
    • Financial Information
      • SEC Filings
    • Corporate Governance
      • Governance Highlights
      • Committee Composition
    • Investor Resources
      • Email Alerts
      • IR Contacts
  • Join Us
  • Contact Us

Events

Events

Past Events
Immunovant Provides Corporate Update
Feb 2, 2021 at 8:00 AM EST
Click here for webcast
Immunovant Announces Positive Topline Results from ASCEND MG, A Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
Aug 25, 2020 at 8:30 AM EDT
Click here for webcast
Immunovant Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a trial of IMVT-1401 In Thyroid Eye Disease, and Provides Corporate Update
Mar 30, 2020 at 8:30 AM EDT
Click here for webcast

Immuno - Toolkits

  • Print Page
  • Email Alerts
  • RSS Feeds
  • IR Contacts
About Us Pipeline Contact Careers

© Immunovant, Inc. | Privacy Policy | Terms of Use